EORTC-1333-GUCG/PEACE III Trial Statement

EORTC is pleased to announce that the phase III EORTC-1333-GUCG/PEACE III trial database is locked. It reached data maturity for its primary endpoint (radiological progression free survival) and analysis has started. The findings will be presented at an upcoming medical meeting and discussed with regulatory authorities.

The phase III EORTC-1333-GUCG/PEACE III trial is a randomised multicentre phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone.

This trial is supported by an investigator driven clinical trial agreement from Bayer HealthCare Pharmaceuticals and Astellas Pharma Europe.


Back to news list

Related News

  • EORTC-1333-GUCG/PEACE III trial endpoint reached

  • Completion of Patient Recruitment for International TIGER Study

  • EORTC Completes Patient Recruitment to Study of Treatment for Rare Cancer High-Grade Uterine Sarcoma

  • Combined hormone/radiotherapy treatment improves event-free and disease-free survival in patients with localised intermediate risk prostate cancer; long-term results from EORTC Trial 22991

  • Revisiting classification in testicular cancer: what has changed?

  • Genito-urinary cancer research looks to the future

  • Prostate cancer patient webinar underlines the importance of measuring the Quality of Life of caregivers

  • Preliminary results confirm that the addition of bone-protecting agents to Radium-233 (Ra-233) treatment can limit fractures in metastatic castration resistant prostate cancer patients

  • Surviving cancer: what is the future?

  • Prostate cancer: the silent man’s disease